Regeneron Pharmaceuticals (REGN) Net Cash Flow Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.44% |
| Dec 31, 2025 | -0.32% |
| Sep 30, 2025 | 26.12% |
| Jun 30, 2025 | -37.92% |
| Mar 31, 2025 | 0.44% |
| Dec 31, 2024 | 15.45% |
| Sep 30, 2024 | -24.58% |
| Jun 30, 2024 | -0.55% |
| Mar 31, 2024 | -20.39% |
| Dec 31, 2023 | 8.73% |
| Sep 30, 2023 | 4.40% |
| Jun 30, 2023 | -81.09% |
| Mar 31, 2023 | 31.38% |
| Dec 31, 2022 | -83.27% |
| Sep 30, 2022 | 15.04% |
| Jun 30, 2022 | 22.27% |
| Mar 31, 2022 | 10.76% |
| Dec 31, 2021 | -7.97% |
| Sep 30, 2021 | 37.79% |
| Jun 30, 2021 | 71.87% |
| Mar 31, 2021 | -29.87% |
| Dec 31, 2020 | 32.06% |
| Sep 30, 2020 | -29.08% |
| Jun 30, 2020 | -12.98% |
| Mar 31, 2020 | 44.01% |
| Dec 31, 2019 | 154.91% |
| Sep 30, 2019 | 48.86% |
| Jun 30, 2019 | -46.70% |
| Mar 31, 2019 | 39.41% |
| Dec 31, 2018 | 6.88% |
| Sep 30, 2018 | 27.99% |
| Jun 30, 2018 | -20.16% |
| Mar 31, 2018 | 43.77% |
| Dec 31, 2017 | -28.61% |
| Sep 30, 2017 | 23.75% |
| Jun 30, 2017 | 21.24% |
| Mar 31, 2017 | 38.56% |
| Dec 31, 2016 | -27.31% |
| Sep 30, 2016 | 50.48% |
| Jun 30, 2016 | -18.68% |
| Mar 31, 2016 | -61.49% |
| Dec 31, 2015 | 22.21% |
| Sep 30, 2015 | 4.36% |
| Jun 30, 2015 | -85.72% |
| Mar 31, 2015 | -9.42% |
| Dec 31, 2014 | 15.44% |
| Sep 30, 2014 | 33.21% |